Reuters: Regulatory News: UPDATE 1-UK watchdog accuses GSK over pay-for-delay drug deals

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-UK watchdog accuses GSK over pay-for-delay drug deals Apr 19th 2013, 06:50 Fri Apr 19, 2013 2:50am EDT LONDON, April 19 (Reuters) - Britain's antitrust watchdog said GlaxoSmithKline and three generic drug companies had undermined competition by striking deals that paid the generic firms to delay the launch of cheap copies of a major antidepressant. The move by the Office of Fair Trading (OFT) is the latest example of regulators trying to curb such deals, following a series of investigations against drug companies by U.S. and European antitrust officials. The OFT alleged on Friday that GSK concluded agreements which infringed competition law with each of Alpharma, Generics (UK) and Norton Healthcare over the supply of paroxetine - a top-selling medicine sold by GSK under the brand name Seroxat. The agency said the agreements, which included substantial payments from GSK to the generic companies in return for their commitment to delay launching their products, amounted to an abuse of a dominant market position. A spokesman for GSK, Britain's biggest drugmaker, said the company disputed the allegations. "We very strongly believe that we acted within the law," he said.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions